Poster presented at the American Society of Hematology 2016 Annual Meeting by Hammersmith Hospital: RT-qPCR and RT-Digital PCR: a comparison of different platforms for the evaluation of residual disease in chronic myeloid leukaemia
Poster presented by the National Cancer Center Research Institute, Japan at the American Association for Cancer Research 2015: Predominance of EGFR mutations responsible for resistance to tyrosine kinase inhibitors among tumor DNAs assessed by picoliter droplet digital PCR analysis of
Poster presented by RUCDR Infinite Biologics at the American Society of Human Genetics 2014: Comparison of NGS solutions for rapid and cost-effective research using degraded FFPE and cancer biobanked specimens with limited quantity
Poster presented by Melissa McConechy of British Columbia Cancer Agency at the American Association of Cancer Research 2014: Circulating tumor DNA: FOXL2 402 – > G mutation can be identified in plasma from adult granulosa cell tumor patients with recurrent disease
RainDance Technologies® is making complex genetics simple. The company’s ultra-sensitive genomic tools enable research of novel non-invasive liquid biopsy applications that should result in more accurate, reliable, cost-effective, and early detection of cancer and other inherited and infectious diseases. Major research institutions and laboratories around the world rely on the performance of RainDance systems. Based outside Boston, Massachusetts, the company supports customers using RainDrop® Digital PCR, as well as the ThunderStorm® and ThunderBolts™ Next-Generation Sequencing Enrichment Systems through its international sales and service operations, as well as a global network of distributors and commercial service providers. Both technology platforms have been recognized by The Scientist as Top 10 Innovations with the RainDrop System winning the award in 2014 and the ThunderStorm System winning the award in 2011.